|
|
|
| Clinical Study of Fibrinolytic Enzyme combined with Atorvastatin in the Treatment of Transient Ischemic Attack |
| LI Yu, JIANG Zongze |
| Chongqing Fuling Central Hospital, Chongqing Fuling 408000, China |
|
|
|
|
Abstract Objective: To investigate the clinical efficacy of plasmin (Plm) combined with atorvastatin (ATV) on transient ischemic attack (TIA) and its impact on the hemorheology and serum matrix metalloproteinase - 9 (MMP-9), hypersensitivity C- reactive protein (hs-CRP) levels in patients. Methods: 100 cases of TIA in our hospital from February 2015 to February 2017 were selected and divided into two groups by random number table. The control group (50 cases) was treated with ATV, and the observation group (50 cases) was additionally treated with Plm. The clinical efficacy, the changes of Hemorheology and serum MMP-9 and hs-CRP levels and the incidence of adverse reactions before and after treatment were recorded and compared between the two groups. Results: After 4 weeks of treatment, the total effective rate of the observation group was 94%, which was significantly higher than that of the control group (74%, P<0.05). Compared with before treatment, the values of high shear viscosity (HBV), whole blood low shear viscosity (LBV), plasma viscosity (SV) and red cell backlog (HCT) were significantly decreased in the two groups after 4 weeks of treatment (P<0.01), and the blood rheology indexes above the observation group were significantly lower than those of the control group (P<0.01). After two weeks of treatment, the serum levels of MMP-9 and hs-CRP were significantly decreased (P<0.01) in the 4 groups, and the decrease in the observation group was more significant (P<0.01). Compared with the control group (10%), the adverse reaction rate in the observation group was 6%, the difference was not statistically significant (P>0.05). Conclusion: The combination of fibrinolytic enzyme and atorvastatin in the treatment of transient ischemic attack can effectively relieve the symptoms and signs of the patients, improve the blood rheology and microcirculation of the body significantly, and the curative effect is better and safe and reliable.
|
|
|
|
|
|
[1] Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. Circulation, 2015, 132(1):40~46.
[2] Marchione P, Vento C, Morreale M, et al. Atorvastatin treatment and carotid plaque morphology in first-ever atherosclerotic transient ischemic attack/Stroke: a case–control study[J].Stroke Cerebrovasc Dis, 2015, 24(1):138~143.
[3] 张俊. 银丹心脑通软胶囊联合纤溶酶治疗脑梗死的疗效观察[J].现代药物与临床,2017,32(2):201~204.
[4] Kernan W N, Viscoli C M, Furie K L, et al. Pioglitazone after ischemic stroke or transient ischemic attack[J]. N Engl Med,2016,64(1):1321~1331.
[5] 高鹏举,王恺.阿托伐他汀联合氯吡格雷治疗短暂性脑缺血发作的临床研究[J].药物评价研究,2017,40(3):361~364.
[6] Wang W, Zhang L, Liu W, et al. Antiplatelet agents for the secondary prevention of ischemic stroke or transient ischemic attack: a network meta-analysis[J].Stroke Cerebrovasc Dis, 2016, 25(5):1081~1089.
[7] 姜丽,王利军,赵岚,等.纤溶酶对急性脑梗死患者血浆血栓前体蛋白水平的影响及意义[J].临床神经病学杂志,2015,28(2):140~142.
[8] 娄卫东,李赵梅,谢紫明.阿托伐他汀联合氯吡格雷治疗短暂性脑缺血发作的疗效及对患者血浆超敏C反应蛋白与脂蛋白相关磷脂酶A_2的影响[J].药物流行病学杂志,2015,24(7):391~393. |
|
|
|
2018, Vol. 24 
